Related Experiment Video
Updated: Jan 28, 2026

A Simple Method to Identify Kinases That Regulate Embryonic Stem Cell Pluripotency by High-throughput Inhibitor Screening
Published on: May 12, 2017
SOX9 is controlled by the BRD4 inhibitor JQ1 via multiple regulation mechanisms
Seong Hwi Hong1, Jueng Soo You2
1Department of Biochemistry, School of Medicine, Konkuk University, Seoul, 05029, South Korea.
Abstract:
SOX9 is a key transcription factor during cell differentiation, sex determination, and tumorigenesis. However, the detailed mechanisms of its targeting strategy remain elusive. To investigate possibilities of targeting SOX9 with epigenetic drugs and the precise underlying mechanisms, two human cancer cell lines were chosen as model systems, which showed high SOX9 expression and anti-tumorigenic effects upon loss of SOX9. Histone acetylation-related screening of a small panel of epigenetic drugs revealed that the bromodomain reader inhibitor JQ1 dramatically downregulated SOX9 through multiple regulation steps, namely, transcription, BRD4-SOX9 protein-protein interaction, and further protein stability. These findings suggest that BRD4 inhibition is a novel therapeutic strategy for diseases characterized by SOX9 overexpression.
Insights
The bromodomain inhibitor JQ1 downregulates SOX9, a key factor in cell differentiation and cancer. This suggests targeting BRD4 offers a new therapeutic strategy for SOX9-driven diseases.
Area of Science:
- Molecular Biology
- Epigenetics
- Cancer Research
Background:
- SOX9 is a crucial transcription factor involved in cell differentiation, sex determination, and cancer development.
- The precise mechanisms governing SOX9's targeting strategy and its therapeutic potential remain unclear.
- Certain human cancers exhibit high SOX9 expression, with its downregulation showing anti-tumorigenic effects.
Purpose of the Study:
- To explore the potential of targeting SOX9 using epigenetic drugs.
- To elucidate the detailed molecular mechanisms underlying SOX9 regulation by epigenetic modulators.
- To investigate the therapeutic implications of targeting SOX9 in cancer.
Main Methods:
- Utilized two human cancer cell lines with high SOX9 expression as model systems.
- Conducted histone acetylation-related screening of epigenetic drugs.
- Investigated the effects of the bromodomain reader inhibitor JQ1 on SOX9 expression and function.
Main Results:
- JQ1 significantly downregulated SOX9 expression through multiple regulatory steps.
- JQ1 affected SOX9 at the transcriptional level.
- JQ1 disrupted BRD4-SOX9 protein-protein interactions and reduced SOX9 protein stability.
Conclusions:
- BRD4 inhibition represents a novel therapeutic strategy for diseases characterized by SOX9 overexpression.
- Targeting the interaction between BRD4 and SOX9 can modulate SOX9 activity.
- Epigenetic drugs like JQ1 offer promising avenues for cancer therapy by targeting key transcription factors.
Related Concept Videos
Regulation of Expression Occurs at Multiple Steps
Transcription results in the generation of precursor (pre-mRNA) that consists of both exons and introns, which needs further processing before being translated to a...
Regulation of Expression Occurs at Multiple Steps
Regulation of Expression at Multiple Steps
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Epigenetic Regulation
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...

